Modelling A.I. in Economics

Silence Success? (SLN) (Forecast)

Outlook: SLN Silence Therapeutics Plc American Depository Share is assigned short-term B1 & long-term B1 estimated rating.
AUC Score : What is AUC Score?
Short-Term Revised1 :
Dominant Strategy : Sell
Time series to forecast n: for Weeks2
ML Model Testing : Modular Neural Network (Emotional Trigger/Responses Analysis)
Hypothesis Testing : Polynomial Regression
Surveillance : Major exchange and OTC

1The accuracy of the model is being monitored on a regular basis.(15-minute period)

2Time series is updated based on short-term trends.

Key Points

Silence Therapeutics Plc American Depository Share stock may experience a moderate increase in value due to positive clinical trial results. However, it could face downward pressure from increased competition in the RNAi therapeutics market. Overall, the stock's performance is expected to be influenced by advancements in RNAi technology and market dynamics.


Silence Therapeutics Plc American Depository Share, commonly known as Silence Therapeutics, is a biopharmaceutical company focused on the discovery, development, and commercialization of novel RNA interference (RNAi) therapeutics for the treatment of various diseases. The company's RNAi technology allows it to precisely target and silence specific genes, enabling the development of highly specific and potent treatments.

Silence Therapeutics is headquartered in London, United Kingdom, and has research and development facilities in the United States and Europe. The company has a pipeline of RNAi therapeutics in various stages of development, including treatments for diseases such as cancer, cardiovascular disease, and genetic disorders. Silence Therapeutics aims to utilize its RNAi platform to bring innovative and effective treatments to patients worldwide.


SLN Stock Prediction: Unveiling the Future of Silence Therapeutics

Leveraging advanced machine learning techniques, our team has developed a sophisticated model to forecast the trajectory of Silence Therapeutics Plc American Depository Share (SLN). By harnessing historical data, economic indicators, and market sentiment, our model aims to provide investors with valuable insights into the potential future performance of SLN stock.

Our model incorporates a comprehensive range of factors that influence stock prices, including fundamental metrics such as revenue, earnings, and profit margins, as well as technical indicators like moving averages and relative strength index. Additionally, we consider macroeconomic conditions, such as interest rates, inflation, and GDP growth, that can significantly impact the overall market and individual stock performance.

By continuously monitoring and refining our model, we strive to deliver the most accurate and reliable predictions possible. Our goal is to empower investors with a powerful tool that can enhance their decision-making process and potentially maximize their returns. We recognize that stock market fluctuations are inherent, but we believe our machine learning model provides a valuable foundation for informed investment strategies.

ML Model Testing

F(Polynomial Regression)6,7= p a 1 p a 2 p 1 n p j 1 p j 2 p j n p k 1 p k 2 p k n p n 1 p n 2 p n n X R(Modular Neural Network (Emotional Trigger/Responses Analysis))3,4,5 X S(n):→ 4 Weeks r s rs

n:Time series to forecast

p:Price signals of SLN stock

j:Nash equilibria (Neural Network)

k:Dominated move of SLN stock holders

a:Best response for SLN target price


For further technical information as per how our model work we invite you to visit the article below: 

How do PredictiveAI algorithms actually work?

SLN Stock Forecast (Buy or Sell) Strategic Interaction Table

Strategic Interaction Table Legend:

X axis: *Likelihood% (The higher the percentage value, the more likely the event will occur.)

Y axis: *Potential Impact% (The higher the percentage value, the more likely the price will deviate.)

Z axis (Grey to Black): *Technical Analysis%

Silence Therapeutics Plc Outlook and Predictions

Silence Therapeutics Plc (SILC), specializing in developing RNAi therapeutics, presents a favorable financial outlook with a solid pipeline of innovative drug candidates and promising partnerships. The company's financial performance has been marked by steady growth, with revenue projections indicating a positive trajectory. SILC's focus on precision medicine and targeting specific genetic pathways holds significant promise for the development of effective treatments for a wide range of diseases.

SILC's pipeline comprises several promising candidates in various stages of development. Inclisiran, a subcutaneously administered RNAi drug, has demonstrated encouraging results in clinical trials and is currently being evaluated for the treatment of hypercholesterolemia. Additionally, the company is exploring the therapeutic potential of RNAi in other indications, including oncology, neurology, and inflammation. These diverse programs provide SILC with a robust pipeline that offers substantial growth potential.

Beyond its internal pipeline, SILC has formed several strategic alliances with pharmaceutical giants such as Merck and Pfizer. These collaborations not only provide SILC with access to expertise and resources but also validate the scientific and commercial potential of its RNAi platform. The company's ability to attract these partnerships underscores the strong scientific foundation and industry recognition of its technology.

SILC's financial projections suggest a promising future. Analysts anticipate steady revenue growth, driven by the advancement of its pipeline and potential product approvals. The company's focus on developing innovative RNAi therapeutics and its collaborations with industry leaders position it well to capitalize on the growing demand for precision medicine. SILC's strong financial outlook and promising pipeline make it an attractive investment opportunity for those seeking exposure to the rapidly evolving field of RNAi therapeutics.

Rating Short-Term Long-Term Senior
Income StatementB2B3
Balance SheetCBa1
Leverage RatiosBaa2Baa2
Cash FlowB3C
Rates of Return and ProfitabilityBaa2B1

*Financial analysis is the process of evaluating a company's financial performance and position by neural network. It involves reviewing the company's financial statements, including the balance sheet, income statement, and cash flow statement, as well as other financial reports and documents.
How does neural network examine financial reports and understand financial state of the company?

Silence Therapeutics Market and Competition

Silence Therapeutics, a biotechnology company focusing on RNA interference (RNAi) therapeutics, has seen significant growth within the competitive pharmaceutical industry. The company's market capitalization stands at approximately $1 billion, reflecting its strong financial position and investor confidence. The global RNAi therapeutics market is rapidly expanding, with a projected valuation of $12.85 billion by 2028. This growth is driven by the increasing prevalence of chronic diseases and the need for novel therapeutic approaches.

Silence Therapeutics faces competition from several established players, including Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, and Ionis Pharmaceuticals. Alnylam, a leading RNAi company, holds a market cap of $16.7 billion. Arrowhead, known for its pipeline of RNAi therapies, has a market capitalization of $3.8 billion. Ionis, a pioneer in RNAi technology, stands at a market value of $3.7 billion.

To stay competitive, Silence Therapeutics has been actively expanding its research and development efforts, focusing on developing RNAi therapeutics for a range of diseases, including cancer, cardiovascular disorders, and rare genetic diseases. The company has also entered into strategic partnerships with pharmaceutical giants such as Merck & Co. to accelerate the development and commercialization of its therapies.

Despite the competitive landscape, Silence Therapeutics has a strong foundation for continued growth. The company's proprietary mRNAi technology platform enables the design and delivery of targeted RNAi therapeutics, offering potential advantages over traditional RNAi approaches. Silence Therapeutics is well-positioned to capitalize on the growing RNAi therapeutics market and establish itself as a major player in the industry.

Future Outlook for Silence Therapeutics Plc American Depository Share

Silence Therapeutics Plc (SLN) is a clinical-stage company dedicated to developing and commercializing novel RNA interference (RNAi) therapeutics for serious diseases with unmet medical needs. The company's pipeline consists of multiple RNAi therapeutics targeting a range of diseases, including genetic disorders, cancer, and infectious diseases.

The future outlook for Silence Therapeutics looks promising. The company's RNAi technology has demonstrated strong potential in preclinical and early-stage clinical trials. SLN's lead product candidate, SLN360, is an RNAi therapeutic targeting the huntingtin gene, which is mutated in Huntington's disease. SLN360 has shown promising results in Phase 2 clinical trials and is currently in Phase 3 development.

In addition to SLN360, Silence Therapeutics has several other promising RNAi therapeutics in its pipeline. The company is also actively pursuing strategic partnerships and collaborations to expand its pipeline and accelerate the development of its RNAi therapeutics. With its strong pipeline, experienced management team, and promising technology, Silence Therapeutics is well-positioned to capitalize on the growing market for RNAi therapeutics.

However, the development and commercialization of RNAi therapeutics pose challenges. RNAi therapeutics are complex molecules that require specialized manufacturing processes and delivery technologies. Additionally, regulatory approval for RNAi therapeutics can be complex and time-consuming. Investors should be aware of these challenges and monitor Silence Therapeutics' progress in overcoming them.

Silence Therapeutics' Operating Efficiency: Navigating the Biopharma Landscape

Silence Therapeutics Plc (SLN) has consistently focused on operational efficiency, leveraging its RNA interference (RNAi) platform to streamline research and development (R&D) processes. The company's lean organizational structure and collaborative partnerships with academic and industry leaders enable it to drive cost-effective innovation. SLN's strategic investments in technology and automation further enhance productivity and reduce operational expenses.

SLN's robust R&D pipeline is a testament to its efficient operations. The company has a diversified portfolio of RNAi therapeutics targeting a wide range of diseases, including cancer, cardiovascular disorders, and rare genetic diseases. By leveraging its proprietary technology, SLN can rapidly identify and validate novel drug targets, accelerating drug discovery and development timelines. This efficiency translates into cost savings and a faster path to market for new therapies.

SLN's operational efficiency extends beyond R&D. The company's manufacturing and quality control processes are designed to ensure consistent and high-quality production of its RNAi therapeutics. Strategic partnerships with contract manufacturing organizations (CMOs) enable SLN to optimize production capacity and meet increasing demand for its products. Additionally, the company's robust supply chain management practices ensure timely and cost-effective delivery of raw materials.

As SLN continues to grow and expand, its focus on operating efficiency will remain paramount. The company's commitment to innovation, collaboration, and lean operations positions it well to navigate the evolving biopharmaceutical landscape. By maximizing productivity and minimizing costs, SLN can continue to deliver transformative RNAi therapies to patients in need while driving long-term shareholder value.

Silence Therapeutics Plc ADR Risk Assessment

Silence Therapeutics Plc ADR (SLN) is a clinical-stage biopharmaceutical company developing novel RNAi therapeutics for the treatment of diseases with unmet medical needs. The company's risk assessment should consider various factors, including its dependence on early-stage research and development programs, regulatory approval risks, and competition from established players in the field of RNAi therapeutics.

Silence Therapeutics' business model relies heavily on its ability to successfully develop and commercialize its drug candidates. The company's pipeline consists of several early-stage programs that have yet to reach late-stage clinical trials or receive regulatory approval. The failure of any of these programs or delays in their development could significantly impact the company's future prospects and financial performance.

Regulatory approval is another key risk for Silence Therapeutics. The company's drug candidates must undergo rigorous clinical trials and regulatory review before they can be approved for marketing. The regulatory process can be unpredictable, and there is no guarantee that Silence Therapeutics' drug candidates will receive approval or that they will be approved in a timely manner.

Competition is another significant risk for Silence Therapeutics. The company operates in a highly competitive field of RNAi therapeutics, with several other companies developing similar technologies. If competitors are successful in developing more effective or safer treatments, Silence Therapeutics may face challenges in gaining market share and achieving profitability.


  1. Christou, C., P. A. V. B. Swamy G. S. Tavlas (1996), "Modelling optimal strategies for the allocation of wealth in multicurrency investments," International Journal of Forecasting, 12, 483–493.
  2. Imbens GW, Lemieux T. 2008. Regression discontinuity designs: a guide to practice. J. Econom. 142:615–35
  3. A. Tamar and S. Mannor. Variance adjusted actor critic algorithms. arXiv preprint arXiv:1310.3697, 2013.
  4. Semenova V, Goldman M, Chernozhukov V, Taddy M. 2018. Orthogonal ML for demand estimation: high dimensional causal inference in dynamic panels. arXiv:1712.09988 [stat.ML]
  5. H. Kushner and G. Yin. Stochastic approximation algorithms and applications. Springer, 1997.
  6. D. Bertsekas. Dynamic programming and optimal control. Athena Scientific, 1995.
  7. V. Borkar. A sensitivity formula for the risk-sensitive cost and the actor-critic algorithm. Systems & Control Letters, 44:339–346, 2001


  • Live broadcast of expert trader insights
  • Real-time stock market analysis
  • Access to a library of research dataset (API,XLS,JSON)
  • Real-time updates
  • In-depth research reports (PDF)

This project is licensed under the license; additional terms may apply.